Primary analysis of phase II results for cemiplimab in patients (pts) with locally advanced basal cell carcinoma (laBCC) who progress on or are intolerant to hedgehog inhibitors (HHIs) Stratigos, A. J., Sekulic, A., Peris, K., Bechter, O., Dutriaux, C., Kaatz, M., Lewis, K. D., Basset-Seguin, N., Chang, A. S., Dalle, S., Fernandez-Orland, A., Licitra, L., Robert, C., Ulrich, C., Hauschild, A., Migden, M. R., Dummer, R., Li, S., Bowler, T., Fury, M. G. ELSEVIER. 2020: S1175–S1176

View details for DOI 10.1016/j.annonc.2020.08.2277

View details for Web of Science ID 000573469102675